On Monday, Nexalin Technology, Inc. (NASDAQ:NXL) announced the publication of a study in the Journal of Alzheimer’s Disease.
The study builds on recent findings from Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) research and further highlights the effectiveness of non-invasive neurostimulation in enhancing brain function and improving cognitive performance in patients with mild Alzheimer’s disease (AD).
The new research involved 46 randomly assigned patients receiving either real DIFS or sham treatment for 30 one-hour sessions over three weeks.
Resting-state functional magnetic resonance imaging (rs-fMRI) was used to track changes in brain activity.
Key Findings of the Study Include:
The study indicated no serious side effects reported among participants.
Despite undergoing twice-daily stimulation sessions over three weeks, elderly patients tolerated the treatment well, with only minor sensations such as tingling that resolved quickly.
The company adds that Alzheimer’s disease affects over 50 million people globally, and it is projected to rise to over 113 million by 2050.
Price Action: NXL stock is down 4.37% at $2.19 during the premarket session at last check Monday.
Read Next:
Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.
Get the latest stock analysis from Benzinga?
This article EXCLUSIVE: Nexalin Technology Says New Data Confirms Implantable Device Improves Cognitive Function, Restores Brain Activity in Alzheimer's Patients originally appeared on Benzinga.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。